Lunit Holds 13th Annual General Meeting of Shareholders... Seungwook Paek Confirmed for Another Term as Chairman of the Board
Medical artificial intelligence (AI) company Lunit announced on March 31 that it held the 13th Annual General Meeting of Shareholders at Bride Valley in Gangnam-gu, Seoul, where all seven proposed agenda items were approved as originally submitted.
At the meeting, the following seven key agenda items were passed: the reappointment of Chairman of the Board Seungwook Paek as inside director, the appointment of independent director Jungwon Kim as a new member of the Audit Committee, five amendments to the Articles of Incorporation—including the introduction of electronic general meetings of shareholders—approval of the 13th term financial statements, approval of the directors’ remuneration limit, and approval and granting of stock options.
Seobum Seok, CEO of Lunit, is giving a presentation at the 13th Annual General Meeting of Shareholders of Lunit held on the 31st at Bride Valley in Gangnam-gu, Seoul. Lunit
View original imageThe main agenda item for this general meeting was the reappointment of Board Chairman Seungwook Paek as inside director. After co-founding Lunit in 2013 and serving as its first CEO, Chairman Paek currently leads the board, spearheading the development of core market strategies, customer analysis, and the advancement of corporate governance, with a particular focus on the United States. As the largest shareholder of Lunit, Chairman Paek is expected to continue driving the company's sustainable long-term growth through this reappointment.
Additionally, Jungwon Kim, who is both an existing independent director and Audit Committee chair, was separately elected in accordance with the revised Commercial Act. As a result, she will serve an additional three years as an independent director and continue her work on the Audit Committee, which is expected to further strengthen the board's oversight functions.
Five amendments to the Articles of Incorporation, aimed at advancing corporate governance, were also approved. These include the introduction of electronic shareholder meetings and expanded methods for exercising voting rights by proxy, enhancing convenience for shareholders in exercising their voting rights. The scope of directors’ fiduciary duties has also been broadened. In addition, the title of “outside director” has been changed to “independent director,” and the mandatory ratio for independent directors has been strengthened. The conditions for appointment and dismissal of Audit Committee members have been reinforced, and the number of separately elected members has been increased to further enhance the independence of the Audit Committee.
Notably, at this general meeting, Craig Hadfield, CEO of Lunit International (formerly Volpara), presented the company’s business achievements and growth strategies in the U.S. breast cancer screening market. CEO Hadfield explained that the U.S. breast cancer screening market, which sees 43 million screenings annually, is facing structural bottlenecks such as shortages of medical personnel and regulatory compliance burdens, and that Lunit International is addressing these issues through a comprehensive “full-stack” solution that covers the entire screening process.
CEO Hadfield went on to state that Lunit International has achieved an average annual sales growth (CAGR) of 21% over the past five years and is targeting 40% year-on-year sales growth this year by leveraging synergies with headquarters products, including Lunit INSIGHT.
In addition, Changho Ahn, Head of Medical Affairs for the Lunit SCOPE division, shared the business strategy and current status of the AI biomarker platform “Lunit SCOPE.” He reported that the division is conducting specific projects with several leading global pharmaceutical companies, including co-development of companion diagnostics (CDx) with some of these partners.
Head Ahn stated that while the ultimate goal is to obtain FDA (U.S. Food and Drug Administration) approval for CDx, meaningful revenue is already being generated at the co-development stage through milestone-based payments and per-case analysis service sales, with clinical trials also contributing to ongoing revenue generation. He added that, following regulatory approval, the use of Lunit solutions in conjunction with therapeutics will serve as a catalyst for revenue, and that this phased expansion is expected to increase sales of Lunit SCOPE by two to three times between 2026 and 2027.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Beomseok Seo, CEO of Lunit, stated, “With the confirmation of Chairman Paek’s reappointment, we have secured continuity for our long-term growth strategy that has persisted since Lunit’s founding. This year, we will accelerate sales growth based on the integration with Lunit International and the business expansion of the Lunit SCOPE division, and we will do our utmost to translate this into tangible profitability and reward the trust of our shareholders.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.